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Abstract
Background: Activation of the trigeminal-autonomic reflex, involving the trigeminal ganglion, the superior salivatory
nucleus and the sphenopalatine ganglion (SPG) is crucial in the pathophysiology of cluster headache (CH). Since
pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) is present both in the SPG and the trigeminal
ganglion (TG) and its role in migraine has been described, our aim was to determine the plasma PACAP-38 levels in
different phases of episodic CH (ECH).
Peripheral cubital fossa blood samples were taken during the ictal and inter-bout periods of male ECH patients and
from age-matched healthy controls (n = 9). Plasma PACAP-38-like immunoreactivity (LI) was measured with specific and
sensitive radioimmunoassay.
Findings: Significantly lower plasma PACAP-38-LI was detected in the inter-bout period of ECH patients than in
healthy controls. However, PACAP-38 was significantly elevated in the plasma during CH attacks as compared to the
inter-bout phase in the same subjects (n = 5).
Conclusions: This exploratory study suggests that PACAP-38 may be released during the attacks of ECH. Further
patients and long-term follow-up are necessary to reveal its function.
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Background
Cluster headache (CH) is a primary, trigeminal-autonomic
headache disorder, manifesting in periodically occurring
unilateral (supra/orbital, temporal) severe pain attacks in
association with intense ipsilateral autonomic symptoms.
The trigeminal-autonomic reflex (TAR) and the hypothal-
amic system (HS) are thought to play important roles in
the mechanism of CH [1]. The significance of TAR is
based on the structural and functional connections
between the trigeminal ganglion (TG), the superior saliva-
tory nucleus being the parasympathetic nucleus of the
facial nerve, the sphenopalatine ganglion (SPG) and otic
ganglion (OG). CH attacks involve activation of the
TG and the SPG resulting in release of neuroactive
neuropeptides such as calcitonin gene-related peptide
(CGRP) and vasoactive intestinal polypeptide (VIP)
[2]. These molecules reach the cranial vessels, the lacrimal
glands and the nasal mucosa via the postganglionic fibers,
leading to conjunctival injection, eyelid and nasal edema,
and rhinorrhea. The circadian and circannual periodicity
of the attacks is attributed to the activation of the HS.
Neurochemical studies have revealed that the VIP-
related neuropeptide pituitary adenylate cyclase-activating
polypeptide-38 (PACAP-38) co-localize [3] in the SPG and
the OG [4], however some PACAP-38-immunoreactivity
was also seen in the TG [5, 6]. It has recently been
described that PACAP-38 mediates the activation of the
trigeminovascular system (TS), and exerts modulatory
function in the sensitization process and migraine head-
ache [7–10]. Human studies have confirmed that intraven-
ously administered PACAP-38 induces migraine-like
headache with marked vascular effects in migraine pa-
tients without aura [11, 12], and that PACAP-38 concen-
trations in the systemic circulation are significantly altered
depending on the phases of migraine headache [13, 14].* Correspondence: tajti.janos@med.u-szeged.hu
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Therefore, PACAP-38 is likely to be an important factor
in migraine pathophysiology; however, there is less evi-
dence concerning its function in other primary headache
disorders such as CH. It is suggested that PACAP-38 may
be involved in the evolution of trigeminal-autonomic
cephalalgias, since this peptide was presented in the TS
[8, 9, 15, 16], and also in the SPG and OG [17, 18] of
humans and rats. Moreover there is a clear increase of
both trigeminal (CGRP) and parasympathetic (VIP) neu-
ropeptides during CH attacks which is normalized when
the pain was controlled in CH [19, 20], and it appears that
activation of the VPAC1 and PAC1 receptors influences
the TAR, the parasympathetic cranial outflow [17, 21].
Based on these data, our aim was to determine if CH
patients are associated with alterations in plasma PACAP-
38-like immunoreactivity (LI) in the inter-bout period and
during the attack in patients suffering from ECH in com-
parison with age- and gender-matched healthy volunteers.
Materials and methods
Participants
Nine male ECH patients treated in our outpatient clinic
(without other known neurological diseases) were selected
in accordance with the criteria of the Headache Classifica-
tion Committee of the International Headache Society.
Nine age-matched male healthy volunteers screened for
non-reported/non-treated headaches served as controls
(age of healthy control subjects: 40.1 ± 12.0 years old,
age of EHC patients: 40.3 ± 9.6 years old). Coexisting
depression in patients was ruled out by Hamilton’s
depression scale. A detailed questionnaire was used to
assess the features of the headache disorder. The clin-
ical and demographic data are summarized in Table 1.
Study design sampling procedures
The study was approved by the Ethics Committee of the
Faculty of Medicine, University of Szeged (87/2009). All
participants gave their written informed consent in
accordance with the Declaration of Helsinki. There were
no restrictions regarding food and drink intake. The
study was performed between 2010 and 2012 years.
Blood samples (6 ml per subject) were taken from the
cubital vein in the routinely used clinical blood sampling
plastic tubes containing 12 mg ethylenediaminetetraace-
tic acid (BD Vacutainer, Becton Dickinson Hungary Plc.,
Hungary) and 1200 IU peptidase inhibitor, aprotinin
(Gordox, Richter Gedeon Plc., Hungary). A single blood
sample was taken in supine position after a rest of
10 min from the controls, whereas samples were taken
from ECH patients during the acute spontaneous attack
(when they produced typical symptoms of CH [22])
and/or in the absolute attack-free, inter-bout period
(out of the cluster episode—by more than a month)
between 8 a.m. and 4 p.m. Samples from both periods
(during attack and outside attack) could be obtained in
5 cases (it was unintentional selection), which could be
used in self-controlled comparison. Patients were asked
not to start their usual treatment before sampling even
during the ictal sampling. Exact date and time of blood
samplings are presented in the Table 2.
Analysis of PACAP-38 in plasma and data analysis
Blood collection, centrifugation, storage and PACAP-38
measurement were carried out with specific and sensi-
tive radioimmunoassay (RIA). Briefly, following centrifu-
gation of the plasma samples (2000 rpm at +4 °C for
10 min), the peptide was extracted from the plasma into
three volumes of absolute alcohol. After precipitation
Table 1 Demographic data and clinical features of CH patients
Questionnaire Mean values and features of ECH
patients (n = 9)
Body mass index: 28.5 ± 5.6
Duration of cluster headache
disease:
7.0 ± 3.8 years
Frequency of cluster episodes
and duration of cluster episode:
2.9 ± 0.8 attack episodes/year
5.0 ± 3.1 weeks
Sessions and seasonality of
headache episodes:
in the evenings/at nights (n = 4), at
dawns (n = 3) and daytime (n = 2)
in spring and summer (n = 4), in
changing seasons (n = 4), in
winter (n = 1)
Intensity and characteristic
of pain:
very strong (n = 6) and severe
(n = 3)
splitting/throbbing (n = 5), sharp/
stabbing (n = 4) headache
Localization and side of pain: orbital, supra/periorbital, temporal
right (n = 6) and left (n = 3) side
Accompanying symptoms: conjunctival injection, lacrimation,
ptosis and eyelid edema, nasal
congestion, rhinorrhea,
vasodilation, facial redness and
flushing
Lifestyle habits: non (n = 4), medium (n = 2) and
excessive (n = 3) smokers,
moderate caffeine consumers (n = 9)
Most commonly used treatments
of ECH patients in the bout
periods:
O2 therapy, sumatriptan, nonsteroidal
anti-inflammatory drugs
(e.g. indomethacin and diclophenac)
Previous attack episode before
the inter-bout blood sampling:
2.8 ± 1.0 months
Beginning of the attack episode
during the ictal blood sampling:
6.4 ± 4.6 days
Duration of headache attack until
the ictal sampling:
2.3 ± 0.6 h
Headache attack frequency per
day in a bout and duration of
headache attack:
1.2 ± 0.7 headache attack/day in a
bout
2.3 ± 0.7 h
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and a second centrifugation, the samples were dried
under a nitrogen flow and resuspended in 300 μl of
assay buffer before RIA determination. The assay was
prepared in 1 mL 0.05 mol/L (pH 7.4) phosphate buffer
containing 0.1 mol/L sodium chloride, 0.25 % (w/v)
bovine serum albumin and 0.05 % (w/v) sodium azide.
The tracer mono-125I-labeled PACAP24–38 (5000 cpm/
tube, 124 Bq/1.72 fmol) was prepared in our laboratory.
Ovine PACAP38 was used as a RIA standard ranging
from 0 to 1000 fmol/mL. The PACAP-38 antiserum
(88111-3, dilution 1:10000 obtained from Abcam UK),
the RIA tracer and the standard or unknown samples
were measured into polypropylene tubes with the assay
buffer. After incubation for 48–72 h at +4 °C, the
antibody-bound peptide was separated from the free
peptide by the addition of separating solution. Following
centrifugation (3000 rpm at +4 °C for 20 min), the
contents of the tubes were gently decanted and the
radioactivity of the precipitates was measured in a
gamma counter (Gamma, type: NZ310). The PACAP-38
concentrations of the unknown samples were read from
calibration curves.
Statistical analysis
Data are expressed as median, interquartile range (IQR),
minimum and maximum or individual values on the
graphs. The distributions of data populations were checked
with the Shapiro-Wilk normality test and the Levene’s test
for analysis of the equality of variances was also applied.
Groups were compared with two sample unpaired and
paired t-tests where appropriate via Monte-Carlo per-
mutation (with 10000 random permutations) due to the
small number of subjects, the unequal variances and the
non-Gaussian distribution of the data of the control
group. Correlations were revealed by the Pearson’s test.
Statistical analyses were performed using the R software
(R Development Core Team, 2002). Significance was
accepted at p < 0.05.
Findings
Differences in plasma PACAP-38-LI between ECH patients
and healthy controls
The level of plasma PACAP-38-LI in the inter-bout
phase of ECH patients was significantly lower (n = 9; me-
dian = 24.4 fmol/ml, IQR = 2.68) than in age and gender
matched healthy volunteers (n = 9; median = 30.5 fmol/ml,
IQR = 8.84; p < 0.026).
Plasma samples from patients during an attack in the
cluster episode exhibited higher PACAP-38 concentrations
(n = 5; median = 28.8 fmol/ml, IQR = 3.40) as compared
to inter-bout samples (n = 9; median = 24.4 fmol/ml,
IQR = 2.68), but these groups were not statistically
compared because of the partly dependent data between
the self-controlled, paired data (n = 5) and the other inter-
bout data (n = 4). No difference was found when ictal
samples (n = 5; median = 28.8 fmol/ml, IQR = 3.40) were
compared to healthy controls (n = 9; median = 30.5 fmol/
ml, IQR = 8.84; p < 0.965) (Fig. 1/a). When we compared
only those subjects that delivered plasma samples
Table 2 Detailed data of blood samplings in ECH patients: date and time, concentrations of PACAP-38 and therapy













Beginning of bout period
(days) and attacks (hours)
before the ictal sampling
Applied therapy
ECH-P1 06 June 2010
03:30 pm
22,70 3.0 15 May 2011
07:35 pm
31,00 Since 14 days, 3 h O2, Sumariptan
ECH-P3 13 June 2010
01:15 pm
28,80 2.5 27 June 2010
07:55 pm
28,80 Since 2 days, 1.5 h O2
ECH-P4 11 July 2010
01:15 pm
20,91 5.0 16 Aug 2010
08:00 am
26,00 Since 7 days, 2.5 h O2, Sumatriptan
ECH-P8 10 Sept 2010
08:30 am
24,40 2.0 15 Oct 2010
02:45 pm
27,30 Since 5 days, 2.5 h O2
ECH-P9 19 Sept 2010
10:30 am
25,20 2.5 NSAIDs
ECH-P10 28 Nov 2010
01:00 pm
24,50 1.5 NSAIDs
ECH-P11 12 Jan 2011
10:00 am
22,20 3.0 NSAIDs
ECH-P12 29 Jan 2012
12:30 pm
23,37 3.5 11 Oct 2011
01:20 pm
29,1 Since 4 days, 2.0 h O2, Sumatriptan
ECH-P13 19 Dec 2011
09:00 am
25,06 2.5 O2, Sumatriptan,
NSAIDs
Mean ± SD 24.1 ± 2.3 2.8 ± 1.0 28.4 ± 1.9 6.4 ± 4.6 days
2.3 ± 0.6 h
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collected from both periods, a significant elevation was
detected in ictal compared to the corresponding inter-
bout samples in a paired comparison as well (n = 5;
median = 24.4 fmol/ml, IQR = 5.20; p < 0.032). As seen in
the illustration four patients showed a clear increase from
inter-bout to ictal sampling and only one patient was with
unchanged value of PACAP-38 (Fig. 1/b).
Positive correlation between inter-bout plasma PACAP-38
concentration and the age of patients
A positive correlation was revealed between the age of
ECH patients and the inter-bout plasma PACAP-38-LI
(n = 9; p < 0.026, r = 0.728) (Fig. 2/b). No correlation was
found between the age of healthy controls and their
plasma PACAP-38-LI (n = 9; p < 0.520, r = 0.248) (Fig. 2/a).
There were no correlations between PACAP-38-LI and
the clinical parameters of ECH patients (data not shown).
Discussion
This is the first study investigating alterations in plasma
PACAP-38 concentration in CH patients; however limi-
tation of our study is the sample size of ECH patients,
especially the sample size of ictal blood samples. Our
results agree with observations in plasma samples from
migraine patients, obtained in the cubital fossa [11, 13]
or the external jugular vein [14].
The source of PACAP-38 is unclear but two sites are
to be discussed, the parasympathetic ganglia SPG and
OT, and the TG, because neurons in ether contain
PACAP-38. It is difficult to separate these sources of
circulation PACAP-38, because they are intermingled.
The stimulation of the superior sagittal sinus elicits
release of both CGRP from the TG and VIP from the
SPG/OT ganglion and the destruction of the trigeminal
nerve aborts their release [10]. This shows interplay
between the sensory and parasympathetic systems. It has
been revealed that PACAP-38 may induce migraine-like
attacks while VIP does not [11, 21, 23]. The role of
PACAP-38 seems to differ from VIP, but there are simi-
larities concerning theirs effects in the peripheral cuta-
neous nociception, which may be mediated by VPAC
receptors [24].
Detailed study on distribution revealed that PACAP
co-localize with CGRP in dura mater sensory fibers. The
supply of parasympathetic innervation of the dura is
scant as compared to that of the cerebral circulation
Fig. 1 Plasma PACAP-38 concentrations in healthy control subjects and ECH patients (a), and changes of PACAP-38 levels in ECH patients between
their inter-bout and ictal periods (b) (n = 5-9/group)
Fig. 2 Association between the age of healthy control subjects and their plasma PACAP-38 level (a), and the age of the ECH patients and their inter-bout
plasma PACAP-38 level (b) (n= 9/group)
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[25]. Thus, it is possible that in both migraine and in
CH the PACAP-38 release emanates mainly from the
trigeminal system.
Our speculation is that the formation of PACAP-38 is
depleted during the inter-bout period in certain nerve
structures, which results in lower plasma PACAP-38
level outside the attacks of CH. Subsequently the chronic-
ally reduced peptide level may be a trigger for sensitization
and altered nociception. During the evolution of nocicep-
tion the concentration of PACAP-38 can increase and it
exerts vasodilation, which is an essential trigger in con-
junction with other unknown factors to the development
of pain. During the attacks the level of PACAP-38 can
reach the normal/control level, which may be a compen-
satory mechanism, but several further investigations are
needed to affirm this theory.
It is also evidenced that the meningeal vasculature
likely contributes to the propagation of the headache
cascade of symptoms, but the vasodilator ability of
PACAP-38 in these circumstances is questionable. It was
showed that the PACAP-38 has high potency to induce
dilation on pressurized rat meningeal arteries [26], while
another study did not find any discernible effect of
PACAP-38 on neither rat nor human samples [27].
Amin et al. have detected significantly elevated plasma
PACAP-38 level following the PACAP-38 infusion in
those migraine patients without aura, who later experi-
enced migraine-like attack [11]. Although the half-life of
this peptide in plasma is short (minutes), it was sug-
gested that the administered PACAP-38 would induce
long-lasting extracranial vasodilation and neurogenic in-
flammation and thereby provoke a migraine attack. The
nature of such a mechanism is still unclear. An alterna-
tive mechanism might be that low levels of PACAP-38 is
entering the CNS and interferes with central sensory
mechanisms active in the migraine or CH brain.
Nevertheless, it is important to mention that elevation
was detected in the plasma PACAP-38 level both in hu-
man migraine studies [11, 14] and experimentally, when
the activation of the TS was provoked with electrical or
chemical methods [7, 14]. However, these studies could
not investigate the difference between the interictal and
normal, healthy plasma PACAP-38 levels.
The main factor determining the levels of PACAP-38 in
the systemic circulation is unidentified; however, it may
originate from endogenous release, damaged elimination,
or de novo synthesis [11]. Significant amount of peptide
can be released from the peripheral (i.e., cranial meninges)
and central branches (i.e., trigeminal caudal nucleus) of
the TG and other PACAP-38-containing structures of the
nervous system (i.e., SPG/OT) during the beginning of the
headache. The activation of TAR is certainly involved in
the neuropeptide overflow, which might result in middle
meningeal artery vasodilation, mast cell degranulation,
and peripheral and central sensitization; concomitantly it
contributes to the development of headache [11, 13, 28].
Although PACAP-38 has not been previously inve-
stigated in CH, the concentrations of CGRP, VIP and
substance P (SP) have already been examined. Regarding
VIP a clinical study has revealed elevated VIP-like im-
munoreactivity in saliva of CH patients during attack
period as compared with the VIP levels during the inter-
ictal phase [29]. Moreover, significantly increased CGRP
and VIP levels were found in the plasma obtained from
the ipsilateral external jugular vein during spontaneous
attacks of ECH patients [19], and in the extracerebral
circulation both during spontaneous and nitroglycerine-
induced attack phase of CH [20, 30], whereas lower
plasma SP levels were detected during histamine-induced
and spontaneously occurring CH attacks when compared
with controls [31]. Of note, similar alterations were
found considering these neuropeptides in migraineurs,
which parallels the concordant changes of PACAP-38-LI
observed in migraine and CH disorders.
Additionally, it should be noted that the role of PACAP
in CH may also be emphasized by the evidences, which
showed that PACAP can modulate the melatonin synthe-
sis, subsequently the circadian and circannual rhythm in
animals (including mammals) [32–34]. However, we did
not find any correlation between the plasma concentration
of PACAP-38 and the date and time of blood sampling.
Moreover, we detected a positive linear correlation
between the inter-bout plasma PACAP-38 level and the
age of ECH patients, which suggests that older age is asso-
ciated with smaller decrease in the concentration of
PACAP-38 outside of cluster period. Our data can be
related to clinical studies, which concluded that the devel-
opment of chronic CH is much less frequent in older than
in younger patients [35, 36], if we consider that a lower
inter-bout plasma PACAP-38 concentration can be a trig-
gering factor of attacks. However, it needs further cases
and data collection to affirm our hypothesis regarding
this association.
Conclusion
Our pilot study provides the first evidence supporting
that PACAP-38 may influence the course of CH. Similar
changes of this peptide in migraine suggest that PACAP-
38 might serve as a marker of primary headache condi-
tions. Further investigations are necessary to determine
the exact functions, targets and signaling pathways of
PACAP-38.
Abbreviations
CGRP, calcitonin gene-related peptide; CH, cluster headache; ECH, episodic
cluster headache; EDTA, ethylenediaminetetraacetic acid; HS, hypothalamic
system; LI, like immunoreactivity; OG, otic ganglion; PACAP-38, pituitary
adenylate cyclase-activating polypeptide-38; RIA, radioimmunoassay; SP,
substance P; SPG, sphenopalatine ganglion; TAR, trigeminal-autonomic reflex;
Tuka et al. The Journal of Headache and Pain  (2016) 17:69 Page 5 of 7
TG, trigeminal ganglion; TS, trigeminovascular system; VIP, vasoactive intestinal
polypeptide
Acknowledgements
This work was supported by the project TÁMOP-4.2.2.A-11/1/KONV-2012-0052,
EUROHEADPAIN (Grant No. 602633), OTKA (PD 104715), the MTA-SZTE
Neuroscience Research Group and the National Brain Research Programs
(Grant No. KTIA_13_NAP-A-III/9., Chronic Pain Research Group: Grant No.
KTIA_NAP_13-2014-0022; Z. Helyes, 888819). Dr. Árpád Párdutz and Dr.
Nikoletta Szabó were supported by the Bolyai Scholarship Programme of
the Hungarian Academy of Sciences.
Authors’ contributions
All authors have read the manuscript and agreed with the submission.
Competing interests
All authors declare that there are no conflicts of interest and they have no
other relevant affiliations or financial involvement concerning this study.
Author details
1Department of Neurology, Faculty of Medicine, University of Szeged,
Semmelweis u. 6, Szeged H-6725, Hungary. 2MTA-SZTE Neuroscience
Research Group, Semmelweis u. 6, Szeged H-6725, Hungary. 3Department of
Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Pécs,
Szigeti u. 12, Pécs H-7624, Hungary. 4János Szentágothai Research Center,
University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary. 5MTA-PTE NAP B
Pain Research Group, University of Pécs, Szigeti u. 12, Pécs H-7624, Hungary.
6Department of Clinical Sciences, Division of Experimental Vascular Research,
Lund University, Sölvegatan 17, BMC A13, Lund 22184, Sweden.
Received: 22 May 2016 Accepted: 22 July 2016
References
1. Goadsby PJ (2002) Pathophysiology of cluster headache: a trigeminal
autonomic cephalgia. Lancet Neurol 1(4):251–7
2. Goadsby PJ, Lipton RB (1997) A review of paroxysmal hemicranias, SUNCT
syndrome and other short-lasting headaches with autonomic feature,
including new cases. Brain 120(Pt 1):193–209
3. Fahrenkrug J, Hannibal J (2004) Neurotransmitters co-existing with VIP or
PACAP. Peptides 25(3):393–401
4. Edvinsson L, Elsas T, Suzuki N, Shimizu T, Lee TJ (2001) Origin and
Co-localization of nitric oxide synthase, CGRP, PACAP, and VIP in the
cerebral circulation of the rat. Microsc Res Tech 53(3):221–8
5. Moller K, Zhang YZ, Hakanson R, Luts A, Sjolund B, Uddman R, Sundler F
(1993) Pituitary adenylate cyclase activating peptide is a sensory
neuropeptide: immunocytochemical and immunochemical evidence.
Neuroscience 57(3):725–32
6. Tajti J, Uddman R, Moller S, Sundler F, Edvinsson L (1999) Messenger
molecules and receptor mRNA in the human trigeminal ganglion. J Auton
Nerv Syst 76(2-3):176–83
7. Tuka B, Helyes Z, Markovics A, Bagoly T, Nemeth J, Mark L, Brubel R, Reglodi D,
Pardutz A, Szolcsanyi J, Vecsei L, Tajti J (2012) Peripheral and central alterations
of pituitary adenylate cyclase activating polypeptide-like immunoreactivity in
the rat in response to activation of the trigeminovascular system. Peptides
33(2):307–16
8. Eftekhari S, Salvatore CA, Johansson S, Chen TB, Zeng Z, Edvinsson L (2015)
Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal
ganglion. Relation to the blood-brain barrier. Brain Res 1600:93–109
9. Palkovits M, Somogyvari-Vigh A, Arimura A (1995) Concentrations of
pituitary adenylate cyclase activating polypeptide (PACAP) in human brain
nuclei. Brain Res 699(1):116–20
10. Zagami AS, Goadsby PJ, Edvinsson L (1990) Stimulation of the superior
sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides
16(2):69–75
11. Amin FM, Hougaard A, Schytz HW, Asghar MS, Lundholm E, Parvaiz AI, de
Koning PJ, Andersen MR, Larsson HB, Fahrenkrug J, Olesen J, Ashina M
(2014) Investigation of the pathophysiological mechanisms of migraine
attacks induced by pituitary adenylate cyclase-activating polypeptide-38.
Brain 137(Pt 3):779–94
12. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M (2009)
PACAP38 induces migraine-like attacks in patients with migraine without
aura. Brain 132(Pt 1):16–25
13. Tuka B, Helyes Z, Markovics A, Bagoly T, Szolcsanyi J, Szabo N, Toth E,
Kincses ZT, Vecsei L, Tajti J (2013) Alterations in PACAP-38-like
immunoreactivity in the plasma during ictal and interictal periods of
migraine patients. Cephalalgia 33(13):1085–95
14. Zagami AS, Edvinsson L, Goadsby PJ (2014) Pituitary adenylate cyclase
activating polypeptide and migraine. Ann Clin Transl Neurol 1(12):1036–40
15. Mulder H, Uddman R, Moller K, Zhang YZ, Ekblad E, Alumets J, Sundler F
(1994) Pituitary adenylate cyclase activating polypeptide expression in
sensory neurons. Neuroscience 63(1):307–12
16. Tajti J, Uddman R, Edvinsson L (2001) Neuropeptide localization in the
“migraine generator” region of the human brainstem. Cephalalgia 21(2):96–101
17. Csati A, Tajti J, Kuris A, Tuka B, Edvinsson L, Warfvinge K (2012) Distribution
of vasoactive intestinal peptide, pituitary adenylate cyclase-activating
peptide, nitric oxide synthase, and their receptors in human and rat
sphenopalatine ganglion. Neuroscience 202:158–68
18. Uddman R, Tajti J, Moller S, Sundler F, Edvinsson L (1999) Neuronal messengers
and peptide receptors in the human sphenopalatine and otic ganglia. Brain
Res 826(2):193–9
19. Goadsby PJ, Edvinsson L (1994) Human in vivo evidence for
trigeminovascular activation in cluster headache. Neuropeptide changes
and effects of acute attacks therapies. Brain 117(Pt 3):427–34
20. Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S (1995) Increase
in plasma calcitonin gene-related peptide from the extracerebral circulation
during nitroglycerin-induced cluster headache attack. Pain 60(2):119–23
21. Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M
(2008) Vasoactive intestinal peptide causes marked cephalic vasodilation,
but does not induce migraine. Cephalalgia 28(3):226–36
22. Headache Classification Committee of the International Headache, S (2013)
The International Classification of Headache Disorders, 3rd edition (beta
version). Cephalalgia 33(9):629–808
23. Amin FM, Hougaard A, Magon S, Asghar MS, Ahmad NN, Rostrup E,
Sprenger T, Ashina M (2016) Change in brain network connectivity during
PACAP38-induced migraine attacks: A resting-state functional MRI study.
Neurology 86(2):180–7
24. Schytz HW, Holst H, Arendt-Nielsen L, Olesen J, Ashina M (2010) Cutaneous
nociception and neurogenic inflammation evoked by PACAP38 and VIP. J
Headache Pain 11(4):309–16
25. Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L (2013) Differentiation of nerve
fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular
system. J Pain 14(11):1289–303
26. Syed AU, Koide M, Braas KM, May V, Wellman GC (2012) Pituitary adenylate
cyclase-activating polypeptide (PACAP) potently dilates middle meningeal
arteries: implications for migraine. J Mol Neurosci 48(3):574–83
27. Grande G, Labruijere S, Haanes KA, MaassenVanDenBrink A, Edvinsson L
(2014) Comparison of the vasodilator responses of isolated human and
rat middle meningeal arteries to migraine related compounds. J Headache
Pain 15:22
28. Vecsei L, Tuka B, Tajti J (2014) Role of PACAP in migraine headaches. Brain
137(Pt 3):650–1
29. Nicolodi M, Del Bianco E (1990) Sensory neuropeptides (substance P,
calcitonin gene-related peptide) and vasoactive intestinal polypeptide in
human saliva: their pattern in migraine and cluster headache. Cephalalgia
10(1):39–50
30. Fanciullacci M, Alessandri M, Sicuteri R, Marabini S (1997) Responsiveness of
the trigeminovascular system to nitroglycerine in cluster headache patients.
Brain 120(Pt 2):283–8
31. Sicuteri F, Fanciullacci M, Geppetti P, Renzi D, Caleri D, Spillantini MG (1985)
Substance P mechanism in cluster headache: evaluation in plasma and
cerebrospinal fluid. Cephalalgia 5(3):143–9
32. Schwartz C, Andrews MT (2013) Circannual transitions in gene expression:
lessons from seasonal adaptations. Curr Top Dev Biol 105:247–73
33. Hannibal J, Ding JM, Chen D, Fahrenkrug J, Larsen PJ, Gillette MU,
Mikkelsen JD (1997) Pituitary adenylate cyclase-activating peptide
(PACAP) in the retinohypothalamic tract: a potential daytime regulator
of the biological clock. J Neurosci 17(7):2637–44
34. Simonneaux V, Ouichou A, Pevet P (1993) Pituitary adenylate cyclase-
activating polypeptide (PACAP) stimulates melatonin synthesis from rat
pineal gland. Brain Res 603(1):148–52
Tuka et al. The Journal of Headache and Pain  (2016) 17:69 Page 6 of 7
35. Donnet A, Lanteri-Minet M, Guegan-Massardier E, Mick G, Fabre N, Geraud G,
Lucas C, Navez M, Valade D, C. Societe Francaise d’Etude des Migraines et
(2007) Chronic cluster headache: a French clinical descriptive study. J Neurol
Neurosurg Psychiatry 78(12):1354–8
36. Dong Z, Di H, Dai W, Pan M, Li Z, Liang J, Zhang M, Zhou Z, Liu R, Yu S
(2013) Clinical profile of cluster headaches in China - a clinic-based study.
J Headache Pain 14(1):27
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Tuka et al. The Journal of Headache and Pain  (2016) 17:69 Page 7 of 7
